Ruff explains his prespecified analysis of the phase 2b AZALEA-TIMI 71 trial, highlighting abelacimab’s efficacy and durability compared to rivaroxaban.
Christian T. Ruff, MD, MPH
Advertisement
Christian T. Ruff, MD, MPH is the Director of General Cardiology in the Cardiovascular Division at Brigham and Women's Hospital.
Articles by Christian T. Ruff, MD, MPH
Ruff discusses his expectations for cardiology for the rest of 2025, including new research into GLP-1 receptor agonists.
Ruff discusses a new analysis of AZALEA-TIMI 71 at ACC.25, which shows that the novel Factor XI inhibitor significantly lowered bleeding in elderly patients.
Abelacimab achieved notably lower levels of free factor XI and fewer bleeding events than standard-of-care rivaroxaban in the Phase 2b trial.
Christian. T. Ruff, MD, MPH describes an analysis of AZALEA-TIMI 71 demonstrating the substantial benefit of abelacimab on bleeding outcomes in patients on antiplatelet therapy.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on HCPLive
1
Q&A: Intensive LDL Lowering and Cardiovascular Prevention Strategies, With Lawrence Leiter, MD
2
Evaluating Clinical and Real-World Evidence in Hypercortisolism
3
Interstitial Lung Abnormalities: Recognition, Risk Stratification, and When to Act
4
Management Strategies for Hypercortisolism
5